RQM+™ Acquires Libra Medical
RQM+, the world’s leading MedTech service provider, today announced the acquisition of Libra Medical, a full-service contract research organization (CRO) that specializes in early-stage clinical trials. Founded in 2007, Libra Medical provides regulatory affairs, clinical operations and quality assurance services to companies that develop complex medical devices and diagnostics products. Libra’s studies take place in the United States, Europe, Australia and Latin America.
“Libra’s deep expertise with first-in-human (FIH) studies for complex devices and diagnostics is an excellent complement for our clinical trials business,” said RQM+ CEO Margaret Keegan. “We will take our clients seamlessly from FIH pilot studies to pivotal to commercial trials all within the same organization while also offering them reimbursement, lab testing and regulatory consulting as their needs evolve. We are honored to have Dr. Tay, the founder of Libra Medical, join RQM+ to continue the strong relationships she has established with the early-stage MedTech community and the FDA.”
With more than 20 years of MedTech expertise, Libra Medical CEO Sew-Wah Tay was the vice president of regulatory and clinical affairs at American Medical Systems (AMS). She also served in leadership roles at multiple MedTech startups, St. Jude Medical and Boston Scientific.
“I am thrilled to now be able to offer my clients a seamless transition from FIH to pilot to pivotal studies,” said Tay. “I look forward to continuing my relationship with clients throughout their product lifecycle by providing them a long-term partnership and comprehensive services through RQM+.”
Tay holds a doctorate degree in biomaterials, a master’s degree in food science and a master’s degree in chemical engineering from the Massachusetts Institute of Technology. She also holds a bachelor’s degree in food science and technology from the University of Pertanian Malaysia.
RQM+ is the leading MedTech service provider with the world’s largest global team of regulatory and quality experts. Building upon 40 years of regulatory expertise, we also provide comprehensive clinical trial, lab and reimbursement services – reducing risk throughout the entire product lifecycle for medical devices, digital therapeutics and diagnostics. With more former FDA, Medicines in Healthcare products Regulatory Agency (MHRA) and notified body regulators than any other firm, the RQM+ team has deep expertise in all clinical specialties. In addition to early- and mid-stage MedTech companies, we currently work with 19 of the top 20 medical device manufacturers and seven of the top 10 IVD companies. For more information, visit RQMplus.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230510005813/en/
Media: Rob Pepper, +1.301.254.6100, email@example.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alipay Now Supports Users to Link Alipay to Their Apple ID in a One-stop Way Within Its App1.6.2023 12:32:00 EEST | Press release
Alipay today announced to launch a new feature for iPhone customers with the latest version of Alipay app to quickly add Alipay to their Apple ID and complete payment authorization one-stop within the app. Alipay app is the world’s first third-party payment app to launch this new feature to greatly optimize iPhone customers’ shopping experience. Updating to iOS 16.4 and later, iPhone customers can search for “Apple” in the Alipay app to enter the “Apple Zone”, add Alipay to their Apple ID and complete the payment authorization. This feature is available for users who have yet linked Alipay as the Apple ID payment method and only takes 3 steps for users to get ready to pay for apps, games or in-app purchases, or subscribe to iCloud+ and Apple Music. Users can manage their accounts from the “Apple Zone”, including setting monthly payment limits and checking up details of each purchase etc. In fact, the “Apple Zone” has become a go-to place for Apple customers to check out discounts every
Forecasting, Monitoring and KI – Swarm Intelligence for the Energy Transition at EM-Power Europe1.6.2023 12:26:00 EEST | Press release
The energy transition does not just change the energy generation technologies we use, but also requires the power grids to be updated. Today, instead of a dozen large-scale power plants, an enormous swarm of power plants all feed into our grid: Several thousand wind farms and over 2.6 million PV systems have been installed in Germany alone – and there is a steep upward trend. This makes our power generation weather dependent: On windless or cloudy days, the energy supply may not match the demand, leading to bottlenecks – or worse – blackouts. To keep the grid frequency at a stable 50.2 hertz, grid operators need yield forecasts. Artificial intelligence (AI) helps process this highly complex information and integrate it into the energy system. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601005572/en/ EM-Power Europe Exhibition (Photo: Solar Promotion GmbH) With millions of solar installations, wallboxes and heat pumps,
European 100 Study Reveals: Despite Year-over-Year Improvements, Tremendous Opportunity to Enhance Hiring with AI, Automation and Experience Remains1.6.2023 12:00:00 EEST | Press release
Phenom released the second annual European Edition of its State of Candidate Experience Report, revealing significant improvement in the use of AI over one year and shining a spotlight on enormous opportunities for companies to enhance job seekers’ experiences through intelligence and automation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601005156/en/ ‘State of Candidate Experience: 2023 Benchmarks Report — European Edition’ reveals, despite year-over-year improvements, tremendous opportunity to enhance hiring with AI, automation and experience remains. The second annual report provides recommendations, including small steps for making big impacts. (Photo: Business Wire) Phenom audited the top 100 European companies of the Global 500 list in three key areas of the talent journey: attraction, engagement and conversion, as well as the use of AI. By viewing their strengths, weaknesses and opportunities for improvement,
In Industry First, PUMA Creates Sustainability Report Podcast Series to Reach Out to Gen-Z1.6.2023 11:00:00 EEST | Press release
Sports company PUMA has created a podcast series to make its 2022 Sustainability Report more accessible and to reach a wider and younger audience. The RE:GEN REPORTS podcast features next-generation thinkers from six countries and distills the content of the report into 10 podcast episodes, of which the first three are available on all major podcast platforms on June 1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601005537/en/ Sports company PUMA has created a podcast series to make its 2022 Sustainability Report more accessible and to reach a wider and younger audience. (Photo: Business Wire) The RE:GEN REPORTS podcast, as well as the recently announced Voices of a Re:Generation project, comes as a direct result of the feedback PUMA received at last year’s Conference of the People, which the company organized to discuss solutions for some of the fashion industry’s most pressing sustainability challenges with Gen-Z rep
invoX Pharma Increases Investment in pHion Therapeutics to Further Develop Next Generation of mRNA Vaccines1.6.2023 11:00:00 EEST | Press release
invoX Pharma Limited (“invoX”), a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK) with an advancing pipeline of innovative products, today announced that it has completed a second tranche of investment in pHion Therapeutics (“pHion”), a next-generation mRNA vaccine company. The transaction supports invoX’s strategy to be a fully integrated biopharmaceutical company and its ongoing commitment to deliver innovative life-saving therapies pHion is developing a pipeline of therapeutic and prophylactic vaccines focussed on oncology and infectious diseases. The company’s proprietary RALA platform can deliver anionic molecules such as mRNA and saRNA in a stealth-like way, evading detection, to generate a potent antigen-specific CD8+ T-cell response. The RALA peptide-based drug delivery system is based on a sequence of 30 amino acids which condenses anionic cargo, irrespective of size, into nanoparticles that are highly efficient at cellular
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom